At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 400 enrolled
Drug / intervention
Ciclesonide +1 moredrug
Likely dose
Ciclesonide 160mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection
In Brief
A Phase 3 clinical trial evaluating Ciclesonide and Placebo for COVID-19. Completed, enrolled 400 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedMay 6, 2020
Enrollment StartJun 8, 2020
Primary CompletionJan 5, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.2 years ago
Interventions
Ciclesonidedrug
160mcg Inhaler
Placebodrug
Matching Placebo Inhaler